• Company to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention

SAN FRANCISCO / Mar 04, 2024 / Business Wire / Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD), to be held from March 6 to 9, 2024, in Florence, Italy. ATTD serves as a premier international forum showcasing cutting-edge advancements in diabetes care, bringing together clinicians, researchers, industry leaders, and policymakers from around the world to exchange knowledge and foster collaboration in the pursuit of innovative solutions for diabetes management.

Key highlights of Better Therapeutics’ participation at ATTD include:

Accepted 2024 ATTD Peer-Reviewed Abstract

The late-breaking abstract findings further validate the use of AspyreRx™ as a safe and effective treatment for patients with type 2 diabetes (T2D). The abstract highlights statistically significant improvements in HbA1c, blood pressure, weight, mood, and quality of life in patients treated with AspyreRx compared to a Standard of Care control group at 180 days. AspyreRx patients also experienced significantly fewer adverse events and medication increases, thereby indicating meaningful reductions in overall healthcare utilization.

Abstract Submission Number: 1282
Presentation Session: E-Poster Viewing
Abstract Title: Randomized, Controlled Trial Of A Novel Digital Therapeutic In Patients With Type 2 Diabetes: BT-001 Pivotal Trial 180 Day Outcomes

Abstracts will be published in the peer-reviewed Journal of Diabetes Technology & Therapeutics.

Industry Symposium

Additionally, Better Therapeutics will host a sponsored industry symposium on Saturday, March 09, 2024, at 8:30 a.m. local time (CET). Speaker Kara Mosesso, ANP-BC, CDCES, Medical Director at Better Therapeutics, will be joined by moderator David Rodbard, MD, Chief Scientific Officer at Biomedical Informatics Consultants. They will discuss the unmet treatment need in T2D, present AspyreRx’s mechanism of action and pivotal data, and highlight the meaningfully enhanced efficacy of AspyreRx plus glucagon-like peptide 1 (GLP-1) agonist use compared to GLP-1 use without AspyreRx.

Exhibition Booth

Attendees will have the opportunity to experience AspyreRx firsthand and learn more about its clinical benefits at the Better Therapeutics exhibition booth. AspyreRx is the first and only U.S. Food and Drug Administration (FDA)-authorized fully digital lifestyle intervention designed to treat T2D.

“We are thrilled to participate in the prestigious ATTD Conference and share our latest research and insights with the global diabetes community,” said Mark Berman, MD, Chief Medical Officer at Better Therapeutics. “We look forward to engaging with fellow experts, exchanging knowledge, and advancing the field of digital therapeutics to improve diabetes outcomes.”

For more information about ATTD 2024, visit: https://attd.kenes.com/

About Better Therapeutics

Better Therapeutics is a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address underlying factors that sustain or worsen cardiometabolic diseases. The Company has developed a proprietary platform for the development of FDA-regulated, software-based solutions for T2D, heart disease and other conditions. The CBT delivered by Better Therapeutics’ PDTs is designed to enable changes in neural pathways of the brain so lasting changes in behavior become possible. Addressing the underlying causes of these diseases has the potential to dramatically improve patient health while lowering healthcare costs. Better Therapeutics’ clinically validated mobile applications are intended to be prescribed by physicians and reimbursed like traditional medicines.

For more information visit: bettertx.com

About AspyreRx

AspyreRx (formerly BT-001) was granted marketing authorization by the FDA in July 2023 as the first prescription-only digital therapeutic to treat adults with type 2 diabetes (T2D). AspyreRx is backed by robust data demonstrating clinically meaningful and sustained reduction in A1c as well as improvements in other markers of cardiometabolic health when used up to 180 days. Using proven techniques that target the underlying psychological, behavioral, and cognitive factors that sustain or worsen T2D, AspyreRx is a self-paced, engaging experience that patients can access from their smartphone. It is prescribed by a healthcare provider in 90-day increments, with proprietary CBT delivered digitally in a weekly step-by-step process. Through interactive therapy lessons, skill-building modules, weekly goal setting and tracking, patients connect changes in behavior to improvements in blood sugar and other biometrics. Each step in the experience builds on the prior to enable and reinforce cognitive restructuring, building the emotional resilience and acceptance needed to make enduring changes.

Indications for Use

AspyreRx is a prescription-only digital therapeutic device intended to provide cognitive behavioral therapy to patients 18 years or older with type 2 diabetes. The device targets behavior to aid in the management of type 2 diabetes in patients who are under the care of a healthcare provider. AspyreRx provides cognitive behavioral therapy as a treatment that should be used adjunctively with standard of care.

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements in this press release include, but are not limited to, statements regarding Better Therapeutics’ expectations related to the efficacy and potential benefits of PDTs, including AspyreRx, and CBT, and their potential treatment applications and their ability to improve clinical outcomes, expectations regarding the rebate agreement and the potential for the rebate agreement to increase accessibility and coverage of Better Therapeutics’ products, and expectations regarding the commercial traction of AspyreRx and partnering and coverage discussions, among others. These forward-looking statements are based on the current expectations of the management of Better Therapeutics and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements including: risks related to Better Therapeutics’ business, such as the willingness of the FDA to authorize PDTs for commercial distribution and insurance companies to reimburse their use, market acceptance of PDTs, including AspyreRx, the risk that the results of previously conducted studies will not be interpreted favorably by the FDA or repeated or observed in ongoing or future studies involving Better Therapeutics’ product candidates and other risks and uncertainties included under the header “Risk Factors” in Better Therapeutics’ quarterly report on Form-10-Q for the fiscal quarter ended September 30, 2023 filed with the Securities and Exchange Commission (“SEC”) on November 09, 2023, and those that are included in any of the Company’s subsequent filings with the SEC.